Insiders who reported open-market trades in the last 12 months at the companies Stephanie Okey files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jeff E. Knight - $3.79M in CRNX purchases and sales in the last 12 months
Stephanie Okey is a corporate insider, tracked as Director of Crinetics Pharmaceuticals, Inc. (CRNX). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Stephanie Okey submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Stephanie Okey been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($1.83M) across all tracked filings.
Stephanie Okey is Director of Crinetics Pharmaceuticals, Inc. (CRNX). 9 SEC Form 4 filings on record going back to 2024, most recently on 1 September 2026. Most recent open-market trade: sold $22K of CRNX on 18 June 2026. Lifetime open-market sales: $1.83M.
Recent transactions
14
The latest 14 SEC Form 4 transactions reported by Stephanie Okey.
InsiderAlpha's records for Stephanie Okey go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. 10 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
